Evidence map›Paper›PMID 42431136›Full record

ArticleESMO open2026

First-in-human phase I study of hypoxia-targeting

H Kurihara, Y Narita, K Ito, H Sato, Y Miyakita, M Takahashi, M Ohno, S Yanagisawa, N T Okita, R Sadachi and 11 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

H KuriharaDiagnostic and Interventional Radiology, Kanagawa Cancer Center Hospital, Yokohama, Japan. Electronic address: kurihara.0420j@kanagawa-pho.jp.
Y NaritaNeurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
K ItoDiagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
H SatoNeurosurgery, Kanagawa Cancer Center Hospital, Yokohama, Japan.
Y MiyakitaNeurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
M TakahashiNeurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
M OhnoNeurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
S YanagisawaNeurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
N T OkitaClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
R SadachiClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
R MachidaClinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
K TateishiNeurosurgery, Yokohama City University, Yokohama, Japan.
Y YoshiiLinqMed Inc., Tokyo, Japan. Electronic address: yoshii.yukie@linqmed.co.jp.
A WakiNational Institutes for Quantum Science and Technology, Chiba, Japan.
H HashimotoNational Institutes for Quantum Science and Technology, Chiba, Japan.
H SuzukiNational Institutes for Quantum Science and Technology, Chiba, Japan.
M-R ZhangNational Institutes for Quantum Science and Technology, Chiba, Japan.
K KawamuraNational Institutes for Quantum Science and Technology, Chiba, Japan.
N HondaPharmacy, National Cancer Center Hospital, Tokyo, Japan.
M YoshimotoExploratory Oncology Research & Clinical Trial Center, National Cancer Center East, Chiba, Japan.
H MatsumotoIsotope Science Center, The University of Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypoxic microenvironments throughout tumors contribute to proliferation and resistance to chemoradiotherapy. Copper-64 diacetyl-bis(N PATIENTS AND

methodsThis phase I dose-escalation trial (STAR-64, jRCT2091220362) evaluated intravenous

resultsEighteen patients received

conclusions

Indexed as

Brain NeoplasmsCoordination ComplexesCopper RadioisotopesOrganometallic CompoundsRadiopharmaceuticalsThiosemicarbazonesAdultAgedFemaleHumansMaleMaximum Tolerated DoseMiddle AgedPositron-Emission TomographyCoordination Complexescopper (II) diacetyl-di(N(4)-methylthiosemicarbazone)Copper RadioisotopesOrganometallic CompoundsRadiopharmaceuticalsThiosemicarbazones(64)Cu-ATSMhypoxiamalignant brain tumorphase I studyradioligand therapy

Identifiers

PMID42431136
PMCPMC13377161

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.